

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 February 2023 (23.02.2023)



(10) International Publication Number
WO 2023/023109 A1

(51) International Patent Classification:

G16H 10/60 (2018.01) G16H 10/65 (2018.01)
G16H 20/17 (2018.01) G16H 15/00 (2018.01)
G16H 40/67 (2018.01) G16H 80/00 (2018.01)
G08B 21/24 (2006.01)

(21) International Application Number:

PCT/US2022/040536

(22) International Filing Date:

17 August 2022 (17.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/233,941 17 August 2021 (17.08.2021) US

(71) Applicant (for US only): **ROCHE DIABETES CARE, INC.** [US/US]; 9115 Hague Road, Indianapolis, Indiana 46250 (US).

(71) Applicant (for DE only): **ROCHE DIABETES CARE GMBH** [DE/DE]; Sandhofer Strasse 116, 68305 Mannheim (DE).

(71) Applicant (for all designated States except DE, US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(72) Inventor: **GALLEY, Paul J.**; c/o Roche Diabetes Care, Inc., 9155 Hague Road, Indianapolis, Indiana 46250 (US).

(74) Agent: **PEDDLE, Ryan A.**; 1717 Arch Street, Suite 3300, Philadelphia, Pennsylvania 19103 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: FACILITATING ADHERENCE TO TASKS DESIGNED TO MAINTAIN OR IMPROVE HEALTH




FIG. 1

(57) Abstract: A user device (e.g., a mobile device) may determine a first notification visibility level for the user health-related event based on a context. The user device may receive data associated with the user health-related event. The user device may determine an adherence level for the user health-related event based on the data associated with the user health-related event. The user device may determine a second notification visibility level for the user health-related event based on comparison of the adherence level to a plurality of predefined adherence thresholds. The user device may communicate, using the second notification visibility level, a notification associated with the user health-related event via the user device upon detection of a triggering event. The user device may group, based on the context, one or more user health-related events into a notification group.

WO 2023/023109 A1

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*